Precision Diagnostics Market By Type (Consumables {Reagents & kits, Assay consumables}, Instruments {NGS systems, PCR instruments, Microarray instruments, Sequencing chips}, Software & Services {Data analytics platforms, AI-based diagnostic software, Bioinformatics services, Clinical decision support tools}), By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), In Situ Hybridization, Microarray, Mass Spectrometry, Immunohistochemistry (IHC), Gene Expression Profiling, CRISPR & Gene Editing Technologies, Liquid Biopsy, Others), By Application (Oncology, Cardiology, Infectious Diseases, Neurology, Rare Diseases, Metabolic Disorders, Prenatal Testing, Others), By Biomarker Type (Genetic Biomarkers, Protein Biomarkers, Metabolic Biomarkers, Cellular Biomarkers, Others), By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles and Market Forecast, 2025 – 2035

---

Industry Outlook

The Precision Diagnostics Market accounted for USD 86.54 Billion in 2024 and USD 98.44 Billion in 2025 is expected to reach USD 357.01 Billion by 2035, growing at a CAGR of around 13.75% between 2025 and 2035. The precision diagnostics aims to discover illnesses by studying what is unique about a person’s genes, habits and home environment. It relies on today’s technology like molecular diagnostics, sequencing genomes and biomarker analysis to catch diseases sooner. So, physicians can use the right treatments for each patient and limit extra surgeries to protect their well-being. The use of precise diagnostics is growing fast since healthcare professionals and researchers agree on the benefits of tailored treatments offered by them, mainly in cancer, rare diseases and chronic conditions. Since there is a rising need for personalized medicine.

Industry Experts Opinion

‘’It's time for precision medicine in women's health—starting with alloimmune disorders of pregnancy, HDFN and FNAIT. How can we bring together advanced diagnostics with therapeutic innovation to bring about an era of precision medicine in women's health?”

• Neha Kumar – Global Head, Commercial Precision Medicine Strategy, Johnson & Johnson

Report Scope:

Market Dynamics

Rising demand for personalized medicine is pushing the need for precise and early diagnostic tools tailored to individual patients.

Precision diagnostics is being driven by the rise in demand for personalized medicine. The goal of personalized medicine is to modify medical treatment based on someone’s genetic makeup, lifestyle and environment. Such a technique depends on precise and early tools that detect diseases at the molecular stage. Precision diagnostics allow doctors to detect particular biomarkers and gene changes in an individual, helping to determine risk for disease, make an exact diagnosis and prepare individual treatment.

Because precision diagnostics consider the unique characteristics of each person, they can make treatment more successful and help avoid adverse side effects. Therefore, more healthcare providers are introducing precision diagnostics to deliver better results for their patients and provide tailored medical care. Due to a rise in complicated and lasting diseases, more people now seek an early and accurate diagnosis. People generally choose diagnostics that can spot illnesses early which aids in preventative care.

People are beginning to rely on genetic tests, liquid biopsies and molecular diagnostic methods, because of their detailed reports. Testing patients using precision diagnostics allows pharmaceutical organizations to use targeted treatments which have helped improve the rate of successful new drug developments. Better outcomes are being emphasized in healthcare so that more procedures are no longer rewarded as in the past. Due to this shift, precision diagnostics can ensure that patients receive customized care sooner. Due to greater awareness, technological developments and helpful policies for healthcare, the precision diagnostics market is gaining importance in present-day medicine and personalized care.

The increasing prevalence of chronic diseases like cancer and cardiovascular disorders requires accurate diagnostics for better treatment outcomes.

More cases of cancer, heart problems and diabetes are sparking growth in the precision diagnostics market. To treat these diseases effectively and avoid complications, detection has to be early and accurate. Not all traditional methods can fully describe the type or level of a disease. Diagnostic tests such as genetic testing, molecular diagnostics and analyzing biomarkers provide detailed and customized information about the disease. By doing this, healthcare providers can find out about health problems earlier and discover the precise reason for them. Treatments are personalized for patients, boosting the chance of overcoming the disease and reducing the chances of side effects. As more people suffer from chronic diseases caused by age and new attitudes, the need for effective diagnostics is increasing quickly.

With cancers, special diagnostics help doctors locate and identify genes or biomarkers which boost the development of tumours. Having this information helps doctors decide whether to prescribe targeted treatment or immunotherapy. As with infections, in heart problems, precise diagnostics identify potential heart disease early, saving doctors from treating severe complications. These tests are also used to check the condition of a disease and treatment results over time in patients. If treatment is tailored to each patient’s test results, they benefit more and lead to more efficient healthcare usage. Since health care is placing more emphasis on prevention and treating ongoing diseases, precise diagnostics are becoming necessary. Increased cases of chronic conditions are encouraging new developments and wider growth in the precision diagnostics industry.

The high cost of precision diagnostic tests and equipment limits access, especially in low- and middle-income regions.

The expense of sophisticated equipment and diagnostic methods is holding back the development of the precision diagnostics market. It takes the most advanced technology like next-gen sequencing, molecular testing and analysis with AI to undertake precision diagnostics, but this renders the equipment and the professionals utilizing it expensive. Numerous healthcare providers, particularly those in the public or rural sectors, struggle to implement such instruments due to their expense. Added to this, preparing these sophisticated diagnostics for use is expensive and the costs tend to be passed on to patients by increasing the cost of the tests. For this reason, the majority of patients in such countries cannot afford personalized care, which contributes to their delayed access to medical specialists.

Healthcare typically focuses on managing uncomplicated medical conditions and might not be able to purchase and utilize high-capacity testing facilities. Since insurance and government subsidies for such testing tend to fall short, patients pay out of pocket in many countries. It means that the better-off in richer regions of the country or those with private insurance benefit from precision diagnostics, while most do not. Because vulnerable populations lack the same opportunities, it retards the global progress of the market and hinders its ability to assist these groups. Discovering how to cut costs by way of new development, policy support and reasonable pricing is imperative.

Integration of AI and machine learning in diagnostics can revolutionize disease prediction and real-time data analysis.

Applying AI and ML technologies to precision diagnostics could help effectively predict diseases and monitor information in real-time. It takes AI algorithms only a short time to analyze countless medical records, doing the job much better than traditional means. With the help of artificial intelligence, doctors observe details in patient readings that may otherwise go unnoticed by humans. This allows healthcare professionals to catch illnesses sooner and with more accuracy, resulting in improved treatments. With AI, it is now possible to predict how a disease will progress and how a patient may react to various treatments. These technologies allow for quick analysis of data, as they track and monitor new information about patients in real time.

The use of this technology aids clinicians in making decisions quicker and improves their accuracy. By allowing machines to perform repetitive tests, doctors and nurses have more time to handle serious illnesses and interact with patients. AI can speed up the process of developing new diagnostics by rapidly reviewing information from clinical tests and genes. Due to the growing use of AI globally, the precision diagnostics market stands to see benefits that help achieve more accuracy, efficient services and broader access to healthcare for people.

The expansion of healthcare infrastructure in emerging economies offers untapped potential for precision diagnostic services.

Healthcare is expanding so rapidly in some developing countries, that there is a vast potential for the precision diagnostics market. Expanded utilization of high-quality healthcare in developing countries has led to more hospitals, diagnostic centres and healthcare establishments being built. As a result of these advances, African hospitals can now utilize advanced diagnostic technology such as precision diagnostics more liberally. Improved access to health facilitates higher numbers of patients in these markets to be diagnosed early and precisely, treated according to their individual needs and gain improved health outcomes.

Private and government entities in developing countries are understanding how important precision diagnostics are to deal with endemic health conditions. With raised awareness and health budgets, these markets can experience rapid growth in the market. Remote and rural regions can now access precision diagnostics, in part through new technology that incorporates telemedicine and digital health. Improvements to healthcare infrastructure in developing countries are developing a larger market for new diagnoses and presenting companies with the chance to support more patients, driving growth and improving global health.

Segment Analysis

Based on type, the Precision Diagnostics Market is segmented into Consumables (Reagents & Kits, Assay Consumables), Instruments (NGS Systems, PCR Instruments, Microarray Instruments, Sequencing Chips), and Software & Services (Data Analytics Platforms, AI-based Diagnostic Software, Bioinformatics Services, Clinical Decision Support Tools). Reagents and kits have the largest market share, as they are used frequently with the many tests conducted daily. The use of consumables will guarantee diagnostic tests are accurate and reliable and thus always in constant demand. Equipment is needed for experiments and represents a larger upfront cost, although its growth rate is consistent with developments. As AI and data analytics aid in deciphering elaborate diagnostic information, the software and services segment is rapidly gaining prominence, albeit with a market share lower than that of consumables.

Based on technology, the Precision Diagnostics Market is segmented into Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), In Situ Hybridization, Microarray, Mass Spectrometry, Immunohistochemistry (IHC), Gene Expression Profiling, CRISPR & Gene Editing Technologies, Liquid Biopsy, and Others. Due to its high precision, speed and ability to analyze numerous genes simultaneously, Next-Generation Sequencing (NGS) leads the way in the personalized medicine market. Due to the use of PCR for detecting genes extensively and ease and economy of use, it holds a strong market share. Although CRISPR and liquid biopsy are rapidly evolving and will play an increasing role in the future, NGS is presently still the primary driving factor behind the market.

Regional Analysis

The North American precision diagnostics market is among the most advanced and developed in the world. Cancer treatment is aided by medical staff who are highly trained and the community’s wide awareness of the disease. Experts are making quick advances in diagnostics, mainly in genetic testing, molecular diagnostics and personalized medicine here. Firms and organizations in the U.S. and Canada routinely join forces to develop effective ways to accurately diagnose diseases. The increased funding and programs put forward by the government are helping the precision medicine market expand. Both major companies and new start-ups lead to the development of new products in the market. More doctors are using AI and big data in diagnostics to aid their decision-making process. More people are seeking early detection of diseases and personalized treatments.

The Asia-Pacific precision diagnostics market is the fastest growing as more people are becoming aware of personalized healthcare, leading to a steady rise in the precision diagnostics market. China, India, Japan and South Korea are looking to upgrade their healthcare and provide improved diagnostic services. Due to greater healthcare requirements and more people becoming chronically ill, both governments and the private sector are using new ways to diagnose diseases. There is an increase in local biotech businesses in the region, allowing for more people to use molecular and genetic tests. Infrastructure and awareness change from one country to another, but this sector is overall on track for growth in precision diagnostics.

Competitive Landscape

In the precision diagnostics market, several major companies and small innovative businesses compete to develop more accurate, speedy and affordable ways to diagnose diseases. Top players like F. Hoffmann-La Roche Ltd., Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Abbott Laboratories use research deals, mergers and buyouts to boost their influence in the market. Advances in technology, including the use of AI, improved sequencing and testing in biopsy samples, help competition in the industry. Working with healthcare organizations and investing more in R&D are influencing the way the market operates. There is a lot of competition among companies as they work towards serving more patients through early disease detection, directed treatment and personalized care in various areas.

Precision Diagnostics Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Recent Developments:

• In January 2024, Siemens Healthineers & the Indian Institute of Science started working together in an AI laboratory for Precision Medicine. It is officially known as the Siemens Healthineers-Computational Data Sciences Collaborative Laboratory for AI in Precision Medicine. The lab is mainly interested in creating open-source AI tools to learn about various neurological diseases. This is a major advancement in AI research for India concerning neurovascular diseases.

Report Coverage:

By Type

• Consumables
  • Reagents & kits
  • Assay consumables
• Instruments
  • NGS systems
  • PCR instruments
  • Microarray instruments
  • Sequencing chips
• Software & Services
  • Data analytics platforms
  • AI-based diagnostic software
  • Bioinformatics services
  • Clinical decision support tools

By Technology

• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• In Situ Hybridization
• Microarray
• Mass Spectrometry
• Immunohistochemistry (IHC)
• Gene Expression Profiling
• CRISPR & Gene Editing Technologies
• Liquid Biopsy
• Others

By Application

• Oncology
• Cardiology
• Infectious Diseases
• Neurology
• Rare Diseases
• Metabolic Disorders
• Prenatal Testing
• Others

By Biomarker Type

• Genetic Biomarkers
• Protein Biomarkers
• Metabolic Biomarkers
• Cellular Biomarkers
• Others

By End User

• Hospitals & Clinics
• Diagnostic Laboratories
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• F. Hoffmann-La Roche Ltd.
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Abbott Laboratories
• Bio-Rad Laboratories, Inc.
• Exact Sciences Corporation
• Agilent Technologies, Inc.
• GE HealthCare Technologies Inc.
• Siemens Healthineers AG
• PerkinElmer, Inc.
• Myriad Genetics, Inc.
• Guardant Health, Inc.
• Foundation Medicine, Inc.
• Natera, Inc.

Frequently Asked Questions (FAQs)